The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's total debt is $63.27 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2022-12-31 | $63.27 B | -17.49% |
2021-12-31 | $76.68 B | -10.89% |
2020-12-31 | $86.05 B | 28.97% |
2019-12-31 | $66.72 B | 65.54% |
2018-12-31 | $40.31 B | 7.87% |
2017-12-31 | $37.36 B | 1.43% |
2016-12-31 | $36.84 B | 16.33% |
2015-12-31 | $31.67 B | 110.99% |
2014-12-31 | $15.01 B | 1.96% |
2013-12-31 | $14.72 B | -6.06% |
2012-12-31 | $15.67 B |
Company | Total debt | differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | $34.87 B | -44.89% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | $18.88 B | -70.15% | ๐บ๐ธ USA |
![]() Amgen AMGN | $61.59 B | -2.65% | ๐บ๐ธ USA |
![]() Biogen BIIB | $6.60 B | -89.55% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | $25.23 B | -60.11% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | $39.37 B | -37.77% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | $31.50 B | -50.21% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | $25.89 B | -59.07% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | $0.25 B | -99.59% | ๐บ๐ธ USA |